177 related articles for article (PubMed ID: 19020145)
21. Methylnaltrexone for opioid-induced constipation in a pediatric oncology patient.
Kissling KT; Mohassel LR; Heintz J
J Pain Symptom Manage; 2012 Jul; 44(1):e1-3. PubMed ID: 22770490
[No Abstract] [Full Text] [Related]
22. Resolution of opioid-induced postoperative ileus in a newborn infant after methylnaltrexone.
Garten L; Degenhardt P; Bührer C
J Pediatr Surg; 2011 Mar; 46(3):e13-5. PubMed ID: 21376180
[TBL] [Abstract][Full Text] [Related]
23. Drug approvals: '08 in review. Methylnaltrexone (Relistor).
Laustsen G; Carrillo F; Johnson J; Smith C
Nurse Pract; 2009 Feb; 34(2):31. PubMed ID: 19155882
[No Abstract] [Full Text] [Related]
24. Subcutaneous methylnaltrexone to restore postoperative bowel function in a long-term opiate user.
Ladanyi A; Temkin SM; Moss J
Int J Gynecol Cancer; 2010 Feb; 20(2):308-10. PubMed ID: 20134275
[TBL] [Abstract][Full Text] [Related]
25. Naloxegol versus Methylnaltrexone for Opioid-Induced Constipation in Critically Ill Patients.
Tobben D; Carpenter S; Kolar R; Merritt T; Young T; Hauser P; Collier T
Ann Pharmacother; 2024 Jul; 58(7):678-684. PubMed ID: 37881915
[TBL] [Abstract][Full Text] [Related]
26. Methylnaltrexone bromide: new drug for the treatment of opioid-induced bowel dysfunction.
Baker DE
Rev Gastroenterol Disord; 2009; 9(3):E84-93. PubMed ID: 19898269
[TBL] [Abstract][Full Text] [Related]
27. Pharmacologic treatment of opioid-induced constipation.
Wang CZ; Yuan CS
Expert Opin Investig Drugs; 2013 Oct; 22(10):1225-7. PubMed ID: 23834367
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study.
Mori M; Ji Y; Kumar S; Ashikaga T; Ades S
Int J Clin Oncol; 2017 Apr; 22(2):397-404. PubMed ID: 27628064
[TBL] [Abstract][Full Text] [Related]
29. Paediatric palliative care: intravenous methylnaltrexone relieves constipation.
Yeomanson D; Chohan O; Mayer A
BMJ Support Palliat Care; 2013 Mar; 3(1):103-5. PubMed ID: 24644335
[TBL] [Abstract][Full Text] [Related]
30. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus.
Neyens R; Jackson KC
J Pain Palliat Care Pharmacother; 2007; 21(2):27-33. PubMed ID: 17844725
[TBL] [Abstract][Full Text] [Related]
31. Methylnaltrexone for opioid-induced constipation in patients with advanced illness: a 3-month open-label treatment extension study.
Lipman AG; Karver S; Cooney GA; Stambler N; Israel RJ
J Pain Palliat Care Pharmacother; 2011; 25(2):136-45. PubMed ID: 21657861
[TBL] [Abstract][Full Text] [Related]
32. Protocol for a randomised control trial of methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients (MOTION).
Patel PB; Brett SJ; O'Callaghan D; Anjum A; Cross M; Warwick J; Gordon AC
BMJ Open; 2016 Jul; 6(7):e011750. PubMed ID: 27412108
[TBL] [Abstract][Full Text] [Related]
33. Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms.
Iyer SS; Randazzo BP; Tzanis EL; Schulman SL; Zhang H; Wang W; Manley AL
Value Health; 2011 Jan; 14(1):177-83. PubMed ID: 21211500
[TBL] [Abstract][Full Text] [Related]
34. Methylnaltrexone: a subcutaneous treatment for opioid-induced constipation in palliative care patients.
Kyle G
Int J Palliat Nurs; 2009 Nov; 15(11):533-40. PubMed ID: 20081727
[TBL] [Abstract][Full Text] [Related]
35. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study.
Portenoy RK; Thomas J; Moehl Boatwright ML; Tran D; Galasso FL; Stambler N; Von Gunten CF; Israel RJ
J Pain Symptom Manage; 2008 May; 35(5):458-68. PubMed ID: 18440447
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of subcutaneous methylnaltrexone in the treatment of opioid-induced constipation: a responder post hoc analysis.
Michna E; Weil AJ; Duerden M; Schulman S; Wang W; Tzanis E; Zhang H; Yu D; Manley A; Randazzo B
Pain Med; 2011 Aug; 12(8):1223-30. PubMed ID: 21810165
[TBL] [Abstract][Full Text] [Related]
37. Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone.
Rosow CE; Gomery P; Chen TY; Stefanovich P; Stambler N; Israel R
Clin Pharmacol Ther; 2007 Jul; 82(1):48-53. PubMed ID: 17392726
[TBL] [Abstract][Full Text] [Related]
38. Use of methylnaltrexone to induce laxation in acutely injured patients with burns and necrotizing soft-tissue infections.
Hewitt K; Lin H; Faraklas I; Morris S; Cochran A; Saffle J
J Burn Care Res; 2014; 35(2):e106-11. PubMed ID: 23877147
[TBL] [Abstract][Full Text] [Related]
39. Methylnaltrexone reverses opioid-induced constipation.
Stephenson J
Lancet Oncol; 2002 Apr; 3(4):202. PubMed ID: 12067677
[No Abstract] [Full Text] [Related]
40. Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials.
Slatkin NE; Lynn R; Su C; Wang W; Israel RJ
J Pain Symptom Manage; 2011 Nov; 42(5):754-60. PubMed ID: 22045373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
